
    
      The study consists of 9 visits. Duplimab will used in the treatment of adult onset atopic
      dermatitis. Qualified subjects will receive 5 dupilumab open-label injections. Skin biopsies/
      skin strips will be obtained at the beginning and the end of treatment. TARC and IgE levels
      will be obtained at the beginning and end of treatment. Subjects will complete daily diaries
      assessing atopic dermatitis symptoms. Patient reported out comes will be completed at each
      visit
    
  